Structural Heart Imaging Market Size, Share and Trends 2024 to 2034

Structural Heart Imaging Market Size and Forecast 2024 to 2034

The global structural heart imaging market size accounted for USD 9.44 billion in 2024 and is expected to exceed around USD 16.76 billion by 2034, growing at a CAGR of 5.91% from 2024 to 2034. The increasing incidence of various congenital diseases is the key factor driving the growth of the structural heart imaging market. Also, the rise in lifestyle-related diseases coupled with the growing prevalence of cardiac disorders can fuel market growth further.

Structural Heart Imaging Market Key Takeaways

• North America led the structural heart imaging market with the largest market share of 36% in 2023.
• Asia Pacific is expected to grow at a CAGR of 6.52% over the projected period.
• By modality, the angiogram segment accounted for the biggest market share of 33% in 2023.
• By modality, the computed tomography (CT) segment is anticipated to grow at the fastest CAGR of 8.12% over the forecast period.
• By procedure, the transcatheter aortic valve replacement (TAVR) segment generated the biggest market share of 36% in 2023.
• By procedure, the surgical aortic valve replacement (SAVR) segment is anticipated to grow at a significant CAGR of 6.1% during the forecast period.
• By application, in 2023, the valvular heart disease segment held the largest share of the market.
• By application, the congenital heart disease segment is projected to grow at the fastest rate in the market over the study period.
• By end use, the hospital and clinics segment has held the largest market share of 55% in 2023.
• By end use, the ambulatory surgical centers segment is expected to show the fastest growth over the projected period.

U.S. Structural Heart Imaging Market Size and Growth 2024 to 2034

The U.S. structural heart imaging market size is exhibited at USD 2.72 billion in 2024 and is projected to be worth around USD 4.83 billion by 2034, growing at a CAGR of 5.90% from 2024 to 2034.

North America dominated the structural heart imaging market in 2023. The dominance of the region can be attributed to the rise in the number of patients suffering from cardiovascular diseases coupled with the heavy spending on medical infrastructure. Furthermore, the U.S. led the market in North America due to the high consumption of alcohol, which has led to an increasing prevalence of heart diseases among the majority population.

• In January 2022, Genesis Medtech Group completed JC Medical (JCM), a cardiac engineering company, in transcatheter valve replacement products for the treatment of low-complexity heart failure.

Asia Pacific is expected to grow at the fastest rate in the structural heart imaging market over the projected period. The growth of the region can be linked to the increase in expenditure on research for cardiovascular diseases and the rise in the older population in the region. Moreover, the high number of the population suffering from work-related stress along with the lack of physical activities are crucial factors contributing to market growth in the region.

Market Overview

Structural heart imaging is a technique that is widely used in the medical industry to examine and screen the heart at the molecular level. The procedure involves the use of reflection of light for creating the interior parts images along with the 2D cross-section analysis. It is then used in assessing and enabling professionals while doing many operative procedures, including detecting blockages in the arteries.

Top 5 Medical Device Companies and their R&D spending in 2022

Role of Artificial Intelligence in the Structural Heart Imaging Market 

The application of Artificial Intelligence (AI) increasingly relies on robust data and appropriate computational tools in the structural heart imaging market. AI may decrease cost and enhance value at the stages of interpretation, image acquisition, and decision-making. Furthermore, high precision is possible with cardiovascular imaging, integrated with big data” from the pathology and electronic health record, which is likely to better personalize therapy and characterize the disease.

• In May 2024, iHridAI unveiled its flagship product, HarmonyCVI, for detailed and precise cardiovascular assessments. HarmonyCVI is a comprehensive AI/ML-based rapid diagnostics and insights tool that aids radiologists and cardiologists in improved analysis of cardiac MRI scans.
• In March 2024, Philips Healthcare launched a new computed tomography system at the European Congress of Radiology (ECR) aimed at the rapidly expanding cardiac coronary CT angiography (CCTA) market. It has a new detector that was created to optimize the use of artificial intelligence (AI) image reconstruction algorithms.

Structural Heart Imaging Market Growth Factors

• The increasing awareness about health and fitness among the majority of the population is the key factor boosting the structural heart imaging market growth.
• The growing usage of transcatheter aortic valve replacement procedures is expected to propel market growth shortly.
• The various initiatives undertaken by the governments of different countries will likely contribute to the market expansion further.

Market Scope

Market Dynamics

Driver

Increasing the use of the TAVR procedure

TAVR is a minimally invasive procedure that can replace a shallow aortic valve without opening the heart. It's also becoming a crucial option for individuals at high risk of complications from open-heart surgery. In the structural heart imaging market, innovations in imaging technology, including 3D imaging and 4D imaging, real-time visualization, and virtual procedures, are commonly observed.

Restraint

Safety concerns

Safety concerns are a major challenge to the structural heart imaging market growth. Safety concerns include a high risk of radiation exposure for (SHDI)s specialists, etc. Moreover, there is a lack of customized training for SHDIs, such as fellowships that emphasize procedural guidance and planning. Also, the adoption of innovative structural heart devices has been frozen, especially in developing economies.

Opportunity

Improved accuracy and resolution

Enhanced accuracy and resolution in structural heart imaging are essential for various reasons. Improved resolution can offer high-quality, accurate diagnosis of heart conditions. Furthermore, precise imaging can help identify individuals at greater risk of complexities during or after the medical procedure. Additionally, imaging offers provide accurate measurements to ensure proper device placement.

• In August 2023, Siemens Healthineers launched the Acuson Origin1, an innovative cardiovascular ultrasound system with new, robust artificial intelligence (AI) features. Created to enhance patient outcomes and help medical professionals perform minimally invasive cardiac procedures more efficiently.

Modality Insights

The angiogram segment dominated the structural heart imaging market in 2023. The dominance of the segment can be attributed to the improved devices, rise in research activities, and effective angiography techniques. Also, heavy funding from private and government organizations is prevalent.

The computed tomography (CT) segment is anticipated to grow at the fastest rate in the structural heart imaging market over the forecast period. The growth of the segment can be linked to the increase in the elderly population, rising demand to seek treatment efficiency, etc. Additionally, CT scanners are increasingly becoming common in medical settings, which helps in decreasing hospitalization times and enhancing disease treatment further.

• In June 2024, Fujifilm Healthcare Americas Corporation, a major provider of diagnostic and enterprise imaging solutions, announced it had received FDA 510(k) clearance for its new compact, 128-slice computed tomography (CT) system, the FCT iStream.

Procedure Insights

The transcatheter aortic valve replacement (TAVR) segment led the global structural heart imaging market in 2023. The dominance of the segment can be linked to the increasing prevalence of high-risk heart disorders among individuals in the middle-aged population, which is a minimally invasive option as compared to conventional treatment. Because of the less invasive nature of this surgery, the rapid recovery of patients is possible.

The surgical aortic valve replacement (SAVR) segment is anticipated to grow at a significant rate in the structural heart imaging market during the forecast period. The growth of the segment can be driven by increasing aortic valve issues in the elderly population, enhanced valve designs, and the designing of advanced bio-compatible materials. However, the risk of procedural death for SAVR is among patients with old age, LV dysfunction, and chronic renal disease.

• In April 2024, The Society of Thoracic Surgeons (STS) introduced new risk calculators for isolated tricuspid valve repair and replacement, surgical aortic valve replacement (SAVR) after prior transcatheter aortic valve replacement (TAVR), and multi-valve surgery with or without coronary artery bypass grafting (CABG).

Application Insights

The valvular heart disease segment held the largest share of the structural heart imaging market. The dominance of the segment is due to the rising prevalence of diseases and infections such as blood infections, rheumatic fever, and high cholesterol among others. Additionally, if not treated well valvular heart disease can convert to fatal complications such as infection, arrhythmia, cardiac arrest, and heart failure.

The congenital heart disease segment is projected to grow at the fastest rate in the structural heart imaging market over the study period. The growth of the segment can be credited to the rise in birth rates because this disease is associated with heart shape and heart structure by birth. Furthermore, CHDs can significantly affect the heart structure, causing blood to flow too slowly, abnormally, or not at all. Congenital heart disease is the most common type of birth defect, affecting nearly 1 in 100 babies.

• In October 2024, Reliance Foundation announced that it is launching the New Health Seva Plan to offer crucial screenings and treatments for children, adolescent girls, and women. The scheme will provide free screening and treatment for congenital heart disease among 50,000 children.

End-use Insights

The hospital segment dominated the structural heart imaging market in 2023. This is due to the enhanced medical infrastructure of clinics and hospitals, innovative devices, and the availability of skilled medical professionals. Hospitals provide comprehensive treatment and care for various heart conditions. In addition, hospitals are well equipped with innovative diagnostic tools that aid in precise and timely diagnosis of heart disorders.

The ambulatory surgical centers segment is expected to show the fastest growth in the structural heart imaging market over the projected period. The growth of the segment can be driven by the easy availability of equipment, expanding infrastructure, and cost-effective surgery options provided by these centers. Furthermore, ambulatory surgical centers offer a more convenient, comfortable, and patient-oriented experience than outpatient settings in hospitals.

Structural Heart Imaging Market Companies

• GE Healthcare
• Siemens Healthineers AG
• Koninklijke Philips N.V
• Canon Medical System, USA
• Boston Scientific Corporation
• Medtronic
• Edwards Lifesciences Corporation
• Bracco
• FUJIFILM Holdings Corporations
• Hitachi, Ltd

Recent Developments

• In October 2023, GE Healthcare introduced its improved venue family point-of-care ultrasound system with features like AI-powered caption guidance. That allows the surgeon to perform cardiac examination with real-time guidance.
• In August 2023, Canon Medical announced the launch of their new angiography system, Alphe Cnix/Evolve Edition, for commercial sale in Asian, African, and European countries.
• In September 2022, Edwards Lifesciences declared FDA approval for its innovative SAPIEN 3 Ultra RESILIA TAVR valve. The device combines the company’s RESILIA tissue technology with the SAPIEN 3 Ultra TAVR device.

Latest Announcements by Market Leaders

• In October 2024, GE HealthCare announced CareIntellect for Oncology, a new cloud-first application that combined multi-modal patient data from disparate systems into a single view, using generative AI to summarize clinical notes and reports. 
• In November 2024, Boston Scientific Corporation announced it had entered into a definitive agreement to acquire Cortex, Inc., an Ajax Health company. Cortex is a privately held medical technology company that emphasizes the development of a diagnostic mapping solution.

Segments covered in the report

By Modality

• Echocardiogram
• Angiogram
• CT
• MRI
• Nuclear Imaging
• Others

By Procedure 

• Transcatheter Aortic Valve Replacement (TAVR)
• Surgical Aortic Valve Replacement (SAVR)
• Transcatheter Mitral Valve Repair (TMVR)
• Left Atrial Appendage Closure (LAAC)
• Annuloplasty
• Valvuloplasty
• Others

By Application

• Valvular Heart Disease
• Congenital Heart Disease

By End-use 

• Hospitals And Clinics
• Ambulatory Surgical Centers
• Diagnostic Imaging Centers
• Others

By Geography

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East and Africa